The timing of azithromycin treatment is not associated with the clinical prognosis of childhood Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.
Mycoplasma pneumoniae infection is a major cause of community-acquired pneumonia in children. We performed a retrospective study to evaluate the clinical impact of the timing of azithromycin treatment in children with Mycoplasma pneumoniae pneumonia in high macrolide-resistant prevalence settings.A...
Main Authors: | Dehua Yang, Linghong Chen, Zhimin Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5788379?pdf=render |
Similar Items
-
Novel Knowledge of Macrolide Resistance in <i>Mycoplasma pneumoniae</i> by Azithromycin Exposure
by: Tomohiro Oishi, et al.
Published: (2024-01-01) -
Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
by: Nobuhisa Ishiguro, et al.
Published: (2017-01-01) -
Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia
by: Yu-Chin Chen, et al.
Published: (2020-07-01) -
Macrolide-resistant <it>Mycoplasma pneumoniae</it> in adolescents with community-acquired pneumonia
by: Miyashita Naoyuki, et al.
Published: (2012-05-01) -
Macrolide-Resistant Mycoplasma pneumoniae, United States
by: Xiaotian Zheng, et al.
Published: (2015-08-01)